Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
- Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum?in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.
- The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover's COVID-19 vaccine candidate and will fund its development through licensure.